JP2005200419A5 - - Google Patents

Download PDF

Info

Publication number
JP2005200419A5
JP2005200419A5 JP2005009439A JP2005009439A JP2005200419A5 JP 2005200419 A5 JP2005200419 A5 JP 2005200419A5 JP 2005009439 A JP2005009439 A JP 2005009439A JP 2005009439 A JP2005009439 A JP 2005009439A JP 2005200419 A5 JP2005200419 A5 JP 2005200419A5
Authority
JP
Japan
Prior art keywords
agonist
peroxisome proliferator
composition
responsive receptor
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2005009439A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005200419A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2005200419A publication Critical patent/JP2005200419A/ja
Publication of JP2005200419A5 publication Critical patent/JP2005200419A5/ja
Pending legal-status Critical Current

Links

JP2005009439A 2004-01-16 2005-01-17 癌治療法 Pending JP2005200419A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53723504P 2004-01-16 2004-01-16

Publications (2)

Publication Number Publication Date
JP2005200419A JP2005200419A (ja) 2005-07-28
JP2005200419A5 true JP2005200419A5 (https=) 2008-02-28

Family

ID=34619679

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005009439A Pending JP2005200419A (ja) 2004-01-16 2005-01-17 癌治療法

Country Status (4)

Country Link
US (2) US20050209292A1 (https=)
EP (1) EP1555021A1 (https=)
JP (1) JP2005200419A (https=)
TW (1) TWI297606B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
NZ590774A (en) * 2008-08-07 2012-09-28 Pulmagen Therapeutics Inflammation Ltd Substantially pure 5R enantiomers of pioglitazone and rosiglitazone for treating inflammatory respiratory diseases
WO2013130792A2 (en) * 2012-02-28 2013-09-06 Northwestern University Prodrugs of fluorinated mevalonates to inhibit the mevalonate pathway of streptococcus pneumoniae
US10660882B2 (en) 2012-03-26 2020-05-26 Nippon Chemiphar Co., Ltd. Prophylactic or therapeutic agent for giant cell tumors occurring in bone and soft tissue or for chondrosarcoma
WO2014054798A1 (ja) * 2012-10-04 2014-04-10 独立行政法人国立循環器病研究センター 悪性腫瘍転移抑制用医薬
JP6513576B2 (ja) * 2013-01-14 2019-05-15 ヘルス クリニックス リミテッド 抗がん剤および使用
KR20220000993A (ko) 2013-09-25 2022-01-04 닛뽕 케미파 가부시키가이샤 골·연부에 발생하는 거세포성 종양, 연골육종 또는 골육종의 예방, 치료 또는 전이 예방을 위한 약제, 동맥색전술용 국소 주입제 및 인공골
EP3612177A4 (en) 2017-04-21 2021-01-13 Lunella Biotech, Inc. TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY
US11197872B2 (en) 2017-04-21 2021-12-14 Lunella Biotech, Inc. Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs)
CA3063450A1 (en) 2017-05-19 2018-11-22 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
PH12019502594A1 (en) 2017-05-19 2020-10-26 Lunella Biotech Inc Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
US20240058335A1 (en) * 2021-01-08 2024-02-22 Duke University Methods for treatment of cancer using abl inhibitors and drugs targeting the mevalonate pathway

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605930A (en) * 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
JP3651816B2 (ja) * 1995-07-03 2005-05-25 三共株式会社 動脈硬化症予防および治療剤
IL118778A (en) * 1995-07-03 1999-07-14 Sankyo Co Pharmaceutical compositions for the treatment of arteriosclerosis and xanthoma containing an hmg-coa reductase inhibitor
ATE462433T1 (de) * 1996-12-11 2010-04-15 Dana Farber Cancer Inst Inc Methoden und pharmazeutische zusammensetzungen zur inhibition des tumorwachstums
UA57081C2 (uk) * 1997-06-16 2003-06-16 Пфайзер Продактс Інк. Фармацевтична композиція для лікування раку або доброякісних проліферативних хвороб у ссавців, спосіб лікування, фармацевтична композиція для інгібування ненормального росту клітин у ссавців та спосіб інгібування
US6410802B1 (en) * 1999-04-01 2002-06-25 Esperion Therapeutics, Inc. Methods for synthesizing ether compounds and intermediates therefor
WO2001058491A1 (en) * 2000-02-10 2001-08-16 Takeda Chemical Industries, Ltd. Drug comprising combination
AU7705601A (en) * 2000-07-25 2002-02-05 Merck & Co Inc N-substituted indoles useful in the treatment of diabetes
JP2002128700A (ja) * 2000-08-16 2002-05-09 Sankyo Co Ltd 癌を予防及び治療するための医薬組成物
WO2003053974A1 (en) * 2001-12-21 2003-07-03 Dr. Reddy's Laboratories Ltd. Novel compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
US20040102360A1 (en) * 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy

Similar Documents

Publication Publication Date Title
JP2005200419A5 (https=)
WO2006084474A3 (en) A stable pharmaceutical composition comprising a fixed dose combination of fenofibrate and an hmg-coa reductase inhibitor
RU2007126483A (ru) Гетероциклические ингибиторы аспартилпротеазы
EA200501586A1 (ru) Фармацевтические продукты
NO20045434L (no) En kombinasjon av en NMDA-antagonist og acetylkolinesteraseinhibitorer for behandlingen av Alzheimers sykdom
IL163931A (en) Derivatives of Tetrazycline Compounds Converted by Amino Methyl and Pharmaceutical Preparation Containing Them
NO20033343D0 (no) Farmasöytiske doseringsformer av epothiloner for oral administrasjon
MX2007007843A (es) Formulacion de complejo de inhibidor de 3-hidroxi-3-metil glutaril coa reductasa y agente antihipertensivo, y proceso para su preparacion.
EE04990B1 (et) HMG reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid, nende kasutamine ja saamismeetod
WO2005034908A3 (en) A solid dosage form comprising a fibrate and a statin
EP2079462A4 (en) PHARMACEUTICAL COMPOSITIONS OF HDAC INHIBITORS AND CHELABLE METAL COMPOUNDS AND METALO HDAC HEMMER CHELATE COMPLEXES
BRPI0412557A (pt) forma de dosagem farmacêutica de eventos cardiovasculares
DE602004020649D1 (de) Hdl-verstärkende kombinationstherapie-komplexe
BRPI0410727A (pt) composto, composição farmacêutica, e, uso de um composto
MXPA05007609A (es) Antagonista de un receptor sensible al calcio.
NO20074109L (no) Intravenose formuleringer av PDE-5 inhibitorer
MA31706B1 (fr) Formulations galéniques de composés organiques
WO2008013833A3 (en) Orally dissolvable/disintegrable lyophilized dosage forms containing protected particles
RU2010109452A (ru) Способы и композиции, предназначенные для лечения раковых заболеваний
EA201401042A1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И КОМБИНИРОВАННОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ ИНГИБИТОРЫ HMG-CoA-РЕДУКТАЗЫ И ФОСФОДИЭСТЕРАЗЫ 4, И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ЛЕГКИХ
JP2006512361A5 (https=)
JP2007512347A5 (https=)
BRPI0411623A (pt) forma de dosagem farmacêutica ou dietética, esporopolenina, método para a formação de uma esporopolenina funcionalizada com amina primária ou um outro revestimento de exina, método para a formação de uma esporopolenina funcionalizada com poliamino ou um outro revestimento de exina de um esporo, método para a obtenção de uma esporopolenina funcionalizada com aminoácido ou um outro revestimento de exina de um esporo, esporopolenina funcionalizada ou um outro revestimento de exina de um esporo, forma de dosagem dietética ou flavorizante, método de preenchimento de revestimentos de exina de esporos, uso da forma de dosagem e método de aplicação oral de um ingrediente ativo
EA200801619A1 (ru) Способ улучшения фармакокинетики ингибиторов интегразы вич (варианты), набор и фармацевтическая композиция (варианты)
WO2006091575A3 (en) Method of increasing drug oral bioavailability and compositions of less toxic orotate salts